XLS.SW

Xlife Sciences AG

XLS.SW, Switzerland

Xlife Sciences AG focuses on the development and commercialization of research projects in the life sciences sector. The company's project covers technology platforms, biotechnology/therapies, medical technology, and artificial intelligence/digital health areas that focuses on identifying new therapeutic approaches and biomarkers for common diseases based on human genetic data. It also produces, researches, develops, and manufactures the chemical and active pharmaceutical ingredients for human and veterinary medicines; and offers clinical research organization services. In addition, the company builds a bridge between research/ development and healthcare markets, as well as support researchers and entrepreneurs in the positioning, structuring, development, and implementation of their ideas; and operates as an active ingredient manufacturer. Further, it focuses on identifying innovative biomarkers in the field of kidney diseases; the development of antibody-drug conjugates through a click chemistry approach and microfluidic screening of functional antibodies; and provides Neuromex, a screening instrument for the early-stage detection of neurological diseases. Xlife Sciences AG was founded in 2019 and is headquartered in Zurich, Switzerland.

https://www.xlifesciences.ch

Stock Price

CHF0.00

0%

increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
XLS.SW
stock
XLS.SW

With 50% ownership, Xlife Sciences AG (VTX:XLS) insiders have a lot at stake Yahoo Finance

Read more →

Finn Analysis

(Last Updated 2025-06-30)

Health Score

Price to Earnings Ratio (P/E)

-

Very High

6.05

Low ≥ 50

High ≤ 10

Price to Book Ratio (P/B)

-

Very Low

0.47

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-1.01 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-0.57 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-226.81 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Low

0.77

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 0.00% of the total shares of Xlife Sciences AG

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-06-30

EPS Actual

-0.53

EPS Estimate

—

EPS Difference

0

Surprise Percent

0%

Investing Fit Scorecard

(Last Updated 2025-06-30)

Deep Value
Strong Deep Value(7)
Defensive
Highly Defensive(6.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(5.8)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(1.5)
Momentum
Strong Momentum(7.5)
Net Net
Not Undervalued (Net-Net)(1)
Quality
Low Quality Business(2.5)
Value
Undervalued(7.5)

Income Statement

(Last Updated 2025-06-30)

Revenue

CHF 0

Cost Of Revenue

CHF 0

Gross Profit

CHF 0

Operating Expenses

CHF 0

Operating Income

CHF 0

Interest Expense

CHF 0

Pretax Income

CHF 0

Net Income

CHF 0

Income Tax Expense

CHF 0

EBITDA

CHF 0

Total Other Income Expense Net

CHF 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-06-30)

Cash

CHF 0

Short Term Investments

CHF 0

Receivables

CHF 0

Inventories

CHF 0

Total Current Assets

CHF 0

Property Plant Equipment

CHF 0

Total Assets

CHF 0

Payables

CHF 0

Short Term Debt

CHF 0

Long Term Debt

CHF 0

Total Liabilities

CHF 0

Equity

CHF 0

Trend

Cash Flow

(Last Updated 2025-06-30)

Net Income

CHF 0

Depreciation

CHF 0

Change In Working Capital

CHF 0

Cash From Operations

CHF 0

Capital Expenditures

CHF 0

Cash From Investing

CHF 0

Cash From Financing

CHF 0

Net Change In Cash

CHF 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.